Product information and disease descriptionPlace of product in therapyDisease description
Burden of RAF-altered pediatric low-grade glioma requiring first-line systemic therapy
52 evidence topics · 25 sources
Tovorafenib (DAY101)
RAF-altered pediatric low-grade glioma requiring first-line systemic therapy
- Manufacturer
- Day One Biopharmaceuticals
- Regulatory submission
- Not announced
- Launch
- Not announced
- Last updated